Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Biver F, Goldman S, Luxen A, Monclus M, Forestini M, Mendlewicz J, Lotstra F.

Eur J Nucl Med. 1994 Sep;21(9):937-46.

PMID:
7995287
2.

Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.

Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JP, Guillaume M, Cantineau R, Comar D, et al.

J Cereb Blood Flow Metab. 1995 Sep;15(5):787-97.

PMID:
7673371
3.

Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.

Smith GS, Price JC, Lopresti BJ, Huang Y, Simpson N, Holt D, Mason NS, Meltzer CC, Sweet RA, Nichols T, Sashin D, Mathis CA.

Synapse. 1998 Dec;30(4):380-92.

PMID:
9826230
4.

In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: a film and electronic autoradiographic study.

Biver F, Lotstra F, Monclus M, Dethy S, Damhaut P, Wikler D, Luxen A, Goldman S.

Nucl Med Biol. 1997 May;24(4):357-60.

PMID:
9257335
5.

PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin.

van Dyck CH, Tan PZ, Baldwin RM, Amici LA, Garg PK, Ng CK, Soufer R, Charney DS, Innis RB.

J Nucl Med. 2000 Feb;41(2):234-41.

6.

Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis.

Petit-Taboué MC, Landeau B, Osmont A, Tillet I, Barré L, Baron JC.

J Nucl Med. 1996 Jan;37(1):95-104.

7.

Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging.

Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L.

Psychiatry Res. 1996 Nov 25;68(1):11-22.

PMID:
9027929
8.

Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder.

Larisch R, Klimke A, Mayoral F, Hamacher K, Herzog HR, Vosberg H, Tosch M, Gaebel W, Rivas F, Coenen HH, Müller-Gärtner HW.

Nuklearmedizin. 2001 Aug;40(4):129-34.

PMID:
11556203
9.

Estimation of brain 5HT2 receptor binding potential with a single-dose PET paradigm.

Petit Taboué MC, Baron JC.

Eur J Nucl Med. 1995 Jun;22(6):585-6. No abstract available.

PMID:
7556308
10.

Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach.

Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbøl S, Madsen J, Knudsen GM.

J Cereb Blood Flow Metab. 2003 Aug;23(8):985-96.

PMID:
12902843
11.

Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.

Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB.

Nucl Med Biol. 1999 Aug;26(6):601-8.

PMID:
10587097
12.

Influence of synaptic serotonin level on [18F]altanserin binding to 5HT2 receptors in man.

Larisch R, Klimke A, Hamacher K, Henning U, Estalji S, Hohlfeld T, Vosberg H, Tosch M, Gaebel W, Coenen HH, Müller-Gärtner HW.

Behav Brain Res. 2003 Feb 17;139(1-2):21-9.

PMID:
12642173
13.

Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.

Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX.

Neuroimage. 2012 Feb 15;59(4):3922-32. doi: 10.1016/j.neuroimage.2011.09.045. Epub 2011 Oct 5.

PMID:
21996132
14.

Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography.

Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA, Ravert HT, Crozier WC, Wagner HN Jr.

J Cereb Blood Flow Metab. 1989 Jun;9(3):398-409.

PMID:
2541148
15.

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams SA, Rubin RH.

J Pharmacol Exp Ther. 1996 Nov;279(2):939-47.

PMID:
8930203
16.

Sex difference in 5HT2 receptor in the living human brain.

Biver F, Lotstra F, Monclus M, Wikler D, Damhaut P, Mendlewicz J, Goldman S.

Neurosci Lett. 1996 Feb 2;204(1-2):25-8.

PMID:
8929969
17.

Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.

Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA.

Synapse. 2001 Jul;41(1):11-21.

PMID:
11354009
18.

Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.

Petit-Taboué MC, Landeau B, Barré L, Onfroy MC, Noël MH, Baron JC.

J Nucl Med. 1999 Jan;40(1):25-32.

19.

A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables.

Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, Madsen K, Frøkjaer V, Martiny L, Paulson OB, Knudsen GM.

Neuroimage. 2004 Mar;21(3):1105-13.

PMID:
15006678
20.

Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm.

van Dyck CH, Soares JC, Tan PZ, Staley JK, Baldwin RM, Amici LA, Fu X, Garg PK, Seibyl JP, Charney DS, Innis RB.

Nucl Med Biol. 2000 Nov;27(8):715-22.

PMID:
11150702

Supplemental Content

Support Center